Report DMCA A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a t
* Please fill this form as much details as possible, we will respond to your request within 2 to 3 business days.
* Please fill this form as much details as possible, we will respond to your request within 2 to 3 business days.